Wichan Kanchanatawan1, Alisara Arirachakaran2, Kornkit Chaijenkij3, Niti Prasathaporn4, Manusak Boonard5, Peerapong Piyapittayanun2, Jatupon Kongtharvonskul6. 1. Orthopedics Department, Lerdsin General Hospital, Bangkok, Thailand. 2. Orthopedics Department, Police General Hospital, Bangkok, Thailand. 3. Orthopedics Department, College of Sports Science and Technology, Mahidol University, Bangkok, Thailand. 4. Orthopedics Department, Queen Savang Vadhana Memorial Hospital, Bangkok, Thailand. 5. Orthopedics Department, Srinakarin Hospital, Khonkaen, Thailand. 6. Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Rama VI Road, Rachatevi, Bangkok, 10400, Thailand. Jatupon_kong@hotmail.com.
Abstract
PURPOSE: To compare the clinical outcomes of osteoarthritis indices (WOMAC and Lequesne scores) and adverse events in the treatment of osteoarthritis (OA) of the knee with platelet-rich plasma (PRP) versus hyaluronic acid (HA) or placebo. METHODS: A systematic review and meta-regression were performed to compare outcomes between PRP injections versus HA or placebo. Relevant randomized control trials were identified from Medline and Scopus from date of inception to 13 August 2015. RESULTS: Nine of 551 studies were eligible; 6, 5, 5, 5, 2, 2, 2 and 7 studies were included in pooling of WOMAC total, pain, stiffness and function scores, Lequesne score, IKDC score, EQ-VAS score and adverse events in OA knee patients, respectively. The PRP injections had -15.4 (95 % CI -28.6, -2.3, p = 0.021), lower mean WOMAC total scores, and 8.83 (95 % CI 5.88, 11.78, p < 0.001), 7.37 (95 % CI 4.33, 10.05, p = 0.021) higher mean IKDC and EQ-VAS scores when compared to HA injections. However, PRP injections had no significant differences in WOMAC pain, stiffness and function scores, as well as Lequesne score and adverse events when compared to HA or placebo. CONCLUSION: In short-term outcomes (≤1 year), PRP injection has improved functional outcomes (WOMAC total scores, IKDC score and EQ-VAS) when compared to HA and placebo, but has no statistically significant difference in adverse events when compared to HA and placebo. This study suggests that PRP injection is more efficacious than HA injection and placebo in reducing symptoms and improving function and quality of life. It has the potential to be the treatment of choice in patients with mild-to-moderate OA of the knee who have not responded to conventional treatment. LEVEL OF EVIDENCE: I.
PURPOSE: To compare the clinical outcomes of osteoarthritis indices (WOMAC and Lequesne scores) and adverse events in the treatment of osteoarthritis (OA) of the knee with platelet-rich plasma (PRP) versus hyaluronic acid (HA) or placebo. METHODS: A systematic review and meta-regression were performed to compare outcomes between PRP injections versus HA or placebo. Relevant randomized control trials were identified from Medline and Scopus from date of inception to 13 August 2015. RESULTS: Nine of 551 studies were eligible; 6, 5, 5, 5, 2, 2, 2 and 7 studies were included in pooling of WOMAC total, pain, stiffness and function scores, Lequesne score, IKDC score, EQ-VAS score and adverse events in OA knee patients, respectively. The PRP injections had -15.4 (95 % CI -28.6, -2.3, p = 0.021), lower mean WOMAC total scores, and 8.83 (95 % CI 5.88, 11.78, p < 0.001), 7.37 (95 % CI 4.33, 10.05, p = 0.021) higher mean IKDC and EQ-VAS scores when compared to HA injections. However, PRP injections had no significant differences in WOMAC pain, stiffness and function scores, as well as Lequesne score and adverse events when compared to HA or placebo. CONCLUSION: In short-term outcomes (≤1 year), PRP injection has improved functional outcomes (WOMAC total scores, IKDC score and EQ-VAS) when compared to HA and placebo, but has no statistically significant difference in adverse events when compared to HA and placebo. This study suggests that PRP injection is more efficacious than HA injection and placebo in reducing symptoms and improving function and quality of life. It has the potential to be the treatment of choice in patients with mild-to-moderate OA of the knee who have not responded to conventional treatment. LEVEL OF EVIDENCE: I.
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Lawrence P Lai; Todd P Stitik; Patrick M Foye; John S Georgy; Varun Patibanda; Boqing Chen Journal: PM R Date: 2015-02-14 Impact factor: 2.298
Authors: Giuseppe Filardo; Berardo Di Matteo; Alessandro Di Martino; Maria Letizia Merli; Annarita Cenacchi; PierMaria Fornasari; Maurilio Marcacci; Elizaveta Kon Journal: Am J Sports Med Date: 2015-05-07 Impact factor: 6.202
Authors: Ken P Ehrhardt; Susan M Mothersele; Andrew J Brunk; Jeremy B Green; Mark R Jones; Craig B Billeaud; Alan David Kaye Journal: Curr Pain Headache Rep Date: 2018-03-19
Authors: Marcus Vinicius Danieli; João Paulo Fernandes Guerreiro; Alexandre Oliveira Queiroz; Hamilton da Rosa Pereira; Daniele Cristina Cataneo Journal: Int Orthop Date: 2020-09-29 Impact factor: 3.075
Authors: Ian A Jones; Ryan Togashi; Melissa L Wilson; Nathanael Heckmann; C Thomas Vangsness Journal: Nat Rev Rheumatol Date: 2019-02 Impact factor: 20.543
Authors: Sebastián Cruz Rodriguez-García; Raul Castellanos-Moreira; Jacqueline Uson; Esperanza Naredo; Terence W O'Neill; Michael Doherty; Mikael Boesen; Hemant Pandit; Ingrid Möller Parera; Valentina Vardanyan; Lene Terslev; Will Uwe Kampen; Maria Antonieta D'Agostino; Francis Berenbaum; Elena Nikiphorou; Irene Pitsillidou; Jenny de la Torre-Aboki; Loreto Carmona Journal: RMD Open Date: 2021-06